Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Comment by stockbuphoonon May 19, 2020 2:33pm
69 Views
Post# 31047285

RE:if they can close the riplazym partnership H1

RE:if they can close the riplazym partnership H1

Realstocky,

Those were corporate slides from last year and the latest Q4 2019 and Q1 2020 do not mention any timeline for partnership except sometime in 2020. Stop trying to mislead people with old failed timelines of H1. They will definitely need financing unless a miracle happens in next 6 weeks but they purposely pushed the deal to anytime in 2020. 

realstocky wrote: like expected, we wont need any financing:

Anticipated Key Milestones (from corp. slides)


1H-2020Expected commercial partnership for Ryplazim™

1H-2020Expected filing of amended BLA with FDA for Ryplazim™ (priority review expected)



<< Previous
Bullboard Posts
Next >>